Evidence map›Paper›PMID 35351237›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022

Low BMI increases all-cause mortality rates in patients with drug-resistant TB.

N Adamashvili, D Baliashvili, G Kuchukhidze, A D Salindri, R R Kempker, H M Blumberg, N Lomtadze, Z Avaliani, M J Magee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

N AdamashviliNational Center for Disease Control and Public Health, Tbilisi, Georgia.
D BaliashviliDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
G KuchukhidzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.
A D SalindriDivision of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, GA.
R R KempkerDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
H M BlumbergDivision of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, GA, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
N LomtadzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Z AvalianiNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
M J MageeDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Emory University · USGeorgia State University · USNational Center for Disease Control and Public Health · GENational Center for Tuberculosis and Lung Disease · GE

Funding

Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)D43TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, HEIMBURGER, DOUGLAS CORBETT · 2017 to 2021
$6.3M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8M
Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitusR01AI153152 · NIAID · EMORY UNIVERSITY · PI MAGEE, MATTHEW JAMES · 2021 to 2025
$3.7M
Pulmonary impairment after tuberculosis in Georgia: Enhancing clinical research capacity to address the intersection of non-communicablediseases and tuberculosisR21TW011157 · FIC · NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC(JOINT STOCK COMPANY) · PI KIPIANI, MAIA, MAGEE, MATTHEW JAMES · 2019 to 2020
$362k
FIC NIH HHS D43 TW007124FIC NIH HHS D43 TW009337FIC NIH HHS R21 TW011157NIAID NIH HHS P30 AI168386NIAID NIH HHS R01 AI153152
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HIV InfectionsTuberculosis, Multidrug-ResistantAdultBody Mass IndexHumansLost to Follow-UpRetrospective Studies

Identifiers

PMID35351237
PMCPMC9757601
OpenAlexW4220710394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.